✨ Free AI Report
Phio Pharmaceuticals Corp.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Phio Pharmaceuticals Corp.
Research Preview

Phio Pharmaceuticals Corp.: Business Overview, Financials & Competitive Analysis

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL self-delivering siRNA technology platform. The company is advancing PH-762, a...

Analyst-debate audio for Phio Pharmaceuticals Corp.

AskCyborg analysts argue the bull and bear cases for Phio Pharmaceuticals Corp. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Phio Pharmaceuticals Corp. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Promising immuno-oncology platform with positive early clinical signals, but extreme capital constraints and clinical stage...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Immuno-Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Phio Pharmaceuticals Corp. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Phio Pharmaceuticals Corp. Overview

Pro stress-test →

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL self-delivering siRNA technology platform. The company is advancing PH-762, a lead candidate in Phase 1b trials for cutaneous squamous cell carcinoma and melanoma, with recent results showing promising safety and efficacy signals.

Strategic Profile

Pro stress-test →

Co-founded by Nobel Prize scientist Craig Mello (RNAi discoverer), Phio leverages advanced gene silencing technology to enhance immune cell effectiveness against tumor cells without requiring specialized drug delivery systems. The company is transitioning from discovery to development with recent leadership strengthening to support regulatory engagement and clinical advancement.

Competitive Landscape

Pro stress-test →

Phio competes in the immuno-oncology space against larger companies with established checkpoint inhibitors and cell therapies. Key differentiators include self-delivering siRNA technology avoiding complex formulations, and focus on underexplored targets (PD-1, BRD4) in skin cancers. Competitive positioning is early-stage with limited direct comparables; clinical validation and manufacturing scale-up are critical

Industry Context

Phio Pharmaceuticals Corp. operates in Biopharmaceutical/Immuno-Oncology.

Key facts

Founded: 2011 · Headquarters: Marlborough, Massachusetts, US · Employees: Unknown · Revenue: N/A · Market cap: $11.6M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Phio Pharmaceuticals Corp..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Phio Pharmaceuticals Corp. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Checkpoint InhibitorsEstablished immuno-oncology class with PD-1/PD-L1 therapies→Cell Therapy PlatformsAdvanced cellular immunotherapy approaches→Early-Stage siRNA OncologyAlternative RNAi and gene silencing technologies→

Compare Phio Pharmaceuticals Corp. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Phio Pharmaceuticals Corp. operates in Biopharmaceutical/Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical/Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about Phio Pharmaceuticals Corp.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Phio Pharmaceuticals Corp. and its top competitor on Cyborg Score”
“What did Phio Pharmaceuticals Corp. do this quarter?”
“Is Phio Pharmaceuticals Corp. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Phio Pharmaceuticals Corp. do?+
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL self-delivering siRNA technology platform. The company is advancing PH-762, a...
What is Phio Pharmaceuticals Corp.'s Cyborg Score?+
Phio Pharmaceuticals Corp. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Phio Pharmaceuticals Corp.'s main competitors?+
Named competitors include Checkpoint Inhibitors, Cell Therapy Platforms, Early-Stage siRNA Oncology. The full competitive landscape is in the AskCyborg report.
How can I get the full Phio Pharmaceuticals Corp. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Phio Pharmaceuticals Corp. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Phio Pharmaceuticals Corp. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9National Bank of Pakistan9RENK Group AG9Lumentum Holdings Inc.9First Abu Dhabi Bank9The Travelers Companies, Inc.9BAE Systems plc9Arista Networks9KLA Corporation9Hermès International S.A.8Enerjisa Enerji A.Ş.8Emirates Central Cooling Systems Corporation8WALLIX Group8StealthGas Inc.8SofWave Medical Ltd.8Himalaya Shipping Ltd.8Bannerman Energy Ltd8Sembcorp Salalah Power & Water Company8MilDef Group